Interpace Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IDXG research report →
Companywww.interpace.com
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
- CEO
- Thomas W. Burnell
- IPO
- 1998
- Employees
- 111
- HQ
- Parsippany, NJ, US
Price Chart
Valuation
- Market Cap
- $7.96M
- P/E
- 1.73
- P/S
- 0.22
- P/B
- 1.78
- EV/EBITDA
- 1.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 62.53%
- Op Margin
- 9.32%
- Net Margin
- 65.25%
- ROE
- 215.31%
- ROIC
- 11.30%
Growth & Income
- Revenue
- $38.73M · -17.47%
- Net Income
- $24.57M · 266.68%
- EPS
- $5.55 · 290.85%
- Op Income
- $4.08M
- FCF YoY
- 45.23%
Performance & Tape
- 52W High
- $2.40
- 52W Low
- $0.70
- 50D MA
- $1.92
- 200D MA
- $1.35
- Beta
- 0.61
- Avg Volume
- 6.07K
Get TickerSpark's AI analysis on IDXG
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 20, 26 | 1315 Capital II, L.P. | other | 9,405,941 |
| Jan 20, 26 | 1315 Capital II, L.P. | other | 19,000 |
| Jan 20, 26 | Ampersand 2018 Limited Partnership | other | 13,861,386 |
| Jan 20, 26 | Ampersand 2018 Limited Partnership | other | 28,000 |
| Dec 1, 24 | McCarthy Christopher | other | 1,111 |
| Jul 27, 24 | McCarthy Christopher | other | 15,112 |
| Feb 1, 24 | McCarthy Christopher | other | 6,045 |
| Jan 31, 24 | McCarthy Christopher | other | 7,556 |
| Dec 1, 23 | McCarthy Christopher | other | 1,095 |
| Jul 31, 23 | McCarthy Christopher | other | 7,556 |
Our IDXG Coverage
We haven't published any research on IDXG yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IDXG Report →